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1-Syntrophin is a member of the family of dystrophin-
associated proteins; it has been shown to recruit
neuronal nitric oxide synthase and the water channel
aquaporin-4 to the sarcolemma by its PSD-95/SAP-90,
Discs-large, ZO-1 homologous domain. To examine the role
of 
 
 
 
1-syntrophin in muscle regeneration, we injected car-
diotoxin into the tibialis anterior muscles of 
 
 
 
1-syntrophin–
 
null (
 
 
 
1syn
 
 
 
/
 
 
 
) mice. After the treatment, 
 
 
 
1syn
 
 
 
/
 
 
 
 muscles
displayed remarkable hypertrophy and extensive ﬁber
splitting compared with wild-type regenerating muscles,
although the untreated muscles of the mutant mice
showed no gross histological change. In the hypertrophied
 
 
muscles of the mutant mice, the level of insulin-like
growth factor-1 transcripts was highly elevated. Interestingly,
 
in an early stage of the regeneration process, 
 
 
 
1syn
 
 
 
/
 
 
 
mice showed remarkably deranged neuromuscular junctions
(NMJs), accompanied by impaired ability to exercise.
The contractile forces were reduced in 
 
 
 
1syn
 
 
 
/
 
 
 
 regenerating
muscles. Our results suggest that the lack of 
 
 
 
1-syntrophin
might be responsible in part for the muscle hypertrophy,
abnormal synapse formation at NMJs, and reduced force
generation during regeneration of dystrophin-deﬁcient
muscle, all of which are typically observed in the early
stages of Duchenne muscular dystrophy patients.
 
Introduction
 
Syntrophins are 58–60 kD peripheral membrane proteins
that have been shown to bind to COOH-terminal domains
of dystrophin, utrophin, dystrobrevins, and their shorter
isoforms (Cartaud et al., 1993; Kramarcy et al., 1994; Ahn
and Kunkel, 1995; Suzuki et al., 1995; Yang et al., 1995). To
date, five isoforms, 
 
 
 
1-, 
 
 
 
1-, 
 
 
 
2-, 
 
 
 
1-, and 
 
 
 
2-syntrophins,
have been identified (Adams et al., 1993; Ahn et al., 1994;
Piluso et al., 2000). All five syntrophins have a similar domain
structure: two pleckstrin homology domains, a PSD-95/
SAP-90, Discs-large, ZO-1 homologous (PDZ)* domain,
and a syntrophin unique domain (Adams et al., 1995; Piluso et
al., 2000), predicting multiple roles in anchoring proteins
at the membrane through the PDZ domain and in signal
transduction. 
 
 
 
1-Syntrophin is expressed mainly in skeletal
muscle, cardiac muscle, and brain. In skeletal muscle, it is
expressed both at the sarcolemma and the neuromuscular
junctions (NMJs). 
 
 
 
1-Syntrophin interacts with dystrophin
at the extrajunctional sarcolemma, whereas it also associates
with utrophin on the crests and with dystrophin in the
depths of the junctional folds at NMJs (Byers et al., 1991;
Sealock et al., 1991). Adams et al. (2000) have reported that
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1-syntrophin–deficient mice have shallow nerve gutters,
abnormal distribution of acetylcholine receptors (AChRs),
and less organized postjunctional folds. However, the mu-
tant mice have no deficiency in their ability to exercise (Ad-
ams et al., 2000). Although the function of 
 
 
 
1-syntrophin is
not fully understood, the PDZ domain of 
 
 
 
1-syntrophin is
known to interact with several molecules. Brenman et al.
(1996) reported the interaction of 
 
 
 
1-syntrophin with neu-
ronal nitric oxide synthase (nNOS) in skeletal muscle. More
recently, we demonstrated the loss of nNOS from the sarco-
lemma in 
 
 
 
1-syntrophin–null (
 
 
 
1syn
 
 
 
/
 
 
 
) muscle (Kameya
et al., 1999). Interestingly, the 
 
 
 
1syn
 
 
 
/
 
 
 
 skeletal muscle was
not dystrophic and showed similar contractile properties to
those of control muscles (Kameya et al., 1999). These results
suggested that the loss of sarcolemmal nNOS is not directly
responsible for muscle degeneration in dystrophin-deficient
muscular dystrophy. We have reported that 
 
 
 
1-syntrophin
also plays a major role in recruiting aquaporin-4 (AQP4), a
water channel, to the sarcolemma in vivo (Yokota et al.,
2000). However, we have observed no direct interaction be-
tween AQP4 and 
 
 
 
1-syntrophin in vitro, suggesting the in-
tervention of as yet unrecognized proteins. In dystrophin-
deficient muscular dystrophy, the loss of dystrophin causes
secondary loss of dystrophin-associated proteins, including
 
 
 
- and 
 
 
 
-dystroglycans, 
 
 
 
-, 
 
 
 
-, 
 
 
 
-, and 
 
 
 
-sarcoglycans, sar-
cospan, dystrobrevins, and 
 
 
 
1- and 
 
 
 
1-syntrophins, from
the sarcolemma (for review see Ozawa et al., 1995). There-
fore, the degeneration/regeneration process, which occurs
throughout the course of the disease, is greatly modified by
the loss of many other functional molecules. In this respect,
molecular dissection of the dystrophin complex is required
to understand the molecular pathogenesis of Duchenne/
Becker muscular dystrophy (DMD). It is a well-known
characteristic of DMD that regeneration is not sufficient to
compensate for the fiber breakdown that occurs throughout
the course of the disease. Whether the lack of dystrophin
and reduced levels of associated proteins directly affect the
ability of fibers of DMD to regenerate is unclear (Cullen,
1997). To clarify the roles of 
 
 
 
1-syntrophin in muscle re-
generation, we injected cardiotoxin into the tibialis anterior
(TA) muscles of wild-type and 
 
 
 
1syn
 
 
 
/
 
 
 
 mice. Cardiotoxin
is known to damage the plasma membrane of myofibers but
leave basal lamina, satellite cells, and nerves intact, allowing
rapid and reproducible muscle regeneration. Toxin-treated
muscles of 
 
 
 
1syn
 
 
 
/
 
 
 
 mice were significantly hypertrophied
at 2–8 wk after injection. Furthermore, the ability to exer-
cise and contractile properties of regenerating muscle of the
mutant mice were considerably impaired. In addition,
 
 
 
1syn
 
 
 
/
 
 
 
 mice had aberrant NMJs from an early stage of re-
generation. These results suggest that the absence of 
 
 
 
1-syn-
trophin resulted in aberrant synapse formation at NMJs, re-
duction of contractile force, and muscle hypertrophy.
 
Results
 
The early phase of muscle regeneration of 
 
 
 
1syn
 
 
 
/
 
 
 
 mice
 
To clarify the roles of 
 
 
 
1-syntrophin in muscle regeneration,
we injected cardiotoxin into TA muscles of wild-type and
 
 
 
1syn
 
 
 
/
 
 
 
 mice and then examined the process of regenera-
tion at various times after injection (from 1 d to 12 wk). He-
 
matoxylin and eosin staining of TA muscles showed that
muscle regeneration of 
 
 
 
1syn
 
 
 
/
 
 
 
 mice was indistinguishable
from that of the wild-type for up to 2 wk after cardiotoxin in-
jection. There was no significant difference in the expression
of myogenic helix-loop-helix transcription factors (MyoD,
myf5, myogenin, and myf6), dystrophin, myosin heavy
chains (MHCs) (embryonic, neonatal, type I, IIa, IIb, IIx), or
laminin-
 
 
 
2 chain between toxin-injected muscles of 
 
 
 
1syn
 
 
 
/
 
 
 
mice and those of wild-type mice (unpublished data).
 
Hypertrophy and extensive fiber splitting 
of 
 
 
 
1syn
 
 
 
/
 
 
 
 regenerating TA muscles at 
2–8 wk after cardiotoxin treatment
 
From 2 wk after injection, regenerating TA muscles of
 
 
 
1syn
 
 
 
/
 
 
 
 mice were much larger than regenerating wild-
type TA muscles (Fig. 1 a). The relative weight of regenerat-
ing 
 
 
 
1syn
 
 
 
/
 
 
 
 TA muscles was much increased at 2, 4, 8, and
12 wk after cardiotoxin injection compared with those of
wild-type muscles. The relative weight of the untreated TA
muscle to body weight of 
 
 
 
1syn
 
 
 
/
 
 
 
 and wild-type mice was
constant, regardless of sex or age.
 
The numbers of myofibers are significantly increased in 
cardiotoxin-injected muscle of 
 
 
 
1syn
 
 
 
/
 
 
 
 mice
 
To determine whether the increase of muscle weight of
 
 
 
1syn
 
 
 
/
 
 
 
 regenerating muscle reflects hyperplasia or hy-
pertrophy of each fiber, the total number of myofibers in a
cross section of TA muscles was counted (Fig. 1 b). In un-
treated left TA muscles, there was no difference in the total
number of muscle fibers between 
 
 
 
1syn
 
 
 
/
 
 
 
 and wild-type
mice. However, the number of fibers after cardiotoxin
treatment was much higher in 
 
 
 
1syn
 
 
 
/
 
 
 
 muscle than in
wild-type muscle (P 
 
 
 
 0.05), although the numbers of fi-
bers increased even in the wild-type muscle after the treat-
ment. As shown in Fig. 2, the increase in numbers of mus-
cle fibers was thought to be due to excessive and extensive
fiber splitting. Typical fiber splitting was found in a hyper-
trophied fiber with several central nuclei (Fig. 2 h). In
transverse sections through the midportion of the TA mus-
cle, we compared the size of TA muscles at each time of
sampling. Fig. 2 shows representative images of nonin-
jected and cardiotoxin-injected muscles of wild-type and
 
 
 
1syn
 
 
 
/
 
 
 
 mice at 4 wk after injection. In untreated mus-
cles, there was no apparent difference in the size of trans-
verse sections between noninjected muscles of wild-type
(Fig. 2 a) and 
 
 1syn
 /  mice (Fig. 2 b), but the size of
 1syn
 /  cardiotoxin-treated muscle (Fig. 2 d) was much
larger than that of wild-type toxin-injected muscle (Fig. 2
c). High power magnification revealed many large caliber
fibers and marked fiber splitting in the  1syn
 /  car-
diotoxin-injected muscles (Fig. 2 h). In wild-type regener-
ating muscles, hypertrophic fibers were less frequent, and
fiber splitting was mild (Fig. 2 g).
Type IIb muscle fibers were preferentially hypertrophied 
in regenerating muscles of  1syn
 /  mice
To examine the relation between fiber types (IIa, IIb, or IIx
type fibers) and hypertrophy or fiber splitting, we next clas-
sified the muscle fibers by their expression of MHC isoforms Abnormal regeneration of  1-syntrophin–deficient muscle | Hosaka et al. 1099
using MHC isoform-specific antibodies. In the TA muscle,
a few fibers expressing slow type MHC I were found mainly
in the central part of the TA muscle. At 2 or 4 wk after toxin
injection, no muscle fiber expressed embryonic/neonatal
MHCs (unpublished data). Next, we separately measured
the cross-sectional area (CSA) of each fiber in the central or
marginal part of cardiotoxin-injected or untreated TA mus-
cles. Fig. 3 shows the frequency distribution of fiber CSAs in
the marginal part of TA muscle at 4 wk after cardiotoxin in-
jection. There was no significant difference in either average
or standard deviation of CSA between untreated wild-type
and   1syn
 /  muscles. However, in regenerating muscle,
the mean CSA in the  1syn
 /  muscle was much larger than
that of the wild-type muscle from 2 wk after cardiotoxin in-
jection. Although the mean CSA of  1syn
 /  regenerating
muscles was equal to that of contralaterals, the fiber size dis-
tribution was significantly different at 4 wk after injection.
There were many large caliber fibers that were not detected
in untreated contralateral TA muscles, together with many
small caliber fibers. These large or small caliber muscle fibers
were often found in the marginal area. Fig. 3 demonstrates
that these fibers were IIb or IIx type fibers. On the other
hand, the fiber size distribution of IIa type was not signifi-
cantly different between genotypes. In wild-type regenerat-
ing muscles, the diversion of CSA was higher from con-
tralaterals, but hypertrophied fibers were less numerous than
Figure 2. Histology of  1syn
 /  TA muscle afer carditoxin injection. 
The largest CSA of TA muscles removed from mice of 
approximately the same body weight at 4 wk after cardiotoxin 
injection. (a–d) Untreated contralateral muscle of wild-type (a) 
and  1syn
 /  (b) mice. Cardiotoxin-injected muscle of wild-type 
(c) and  1syn
 /  (d) mice. The size of  1syn
 /  cardiotoxin-treated 
muscle is much larger than that of wild-type toxin-injected 
muscle, although there was no apparent difference between 
noninjected muscle of wild-type and  1syn
 /  mice. High power 
magnification view of each muscle (e–h). Noninjected muscle of 
wild-type (e) and  1syn
 /  mice (f). Cardiotoxin-injected muscle 
of wild-type mice (g).Cardiotoxin-injected muscle of  1syn
 /  
mice (h) displayed many large caliber fibers and fiber splitting 
(arrowheads). Bars: (a–d) 1 mm; (e–h) 50  m.
Figure 1. Changes in the weight and the number of myofibers in 
TA muscles after cardiotoxin injection. (a) The weight of TA muscle 
was normalized to body weight. Relative weight of regenerating 
 1syn
 /  TA muscles to body weight is significantly increased at 2, 
4, 8, and 12 wk after cardiotoxin injection compared with that of 
regenerating wild-type muscles. Values are mean   SEM for 4–10 
muscles/group. #Significant difference (P   0.05) between 
cardiotoxin-injected muscles of  1syn
 /  ( ) and wild-type ( ) 
mice. *Significant difference (P   0.05) between noninjected ( ) 
and toxin-injected muscles ( ) of wild-type mice. **Significant 
difference (P   0.05) between noninjected ( ) and toxin-injected 
( ) muscles of  1syn
 /  mice. There was no significant difference 
between untreated muscles of wild-type ( ) and  1syn
 /  mice ( ). 
(b) Changes in the number of myofibers in TA muscles after 
cardiotoxin injection. There was no significant difference between 
untreated muscles of wild-type (white bars) and  1syn
 /  mice (grey 
bars), whereas the ratio of increase in the numbers of fibers after 
cardiotoxin treatment was much higher in  1syn
 /  muscle than in 
wild-type muscle. Values are mean   SEM for three to six muscles/
group. *Significant difference (P   0.05) from untreated muscles of 
wild-type mice. #Significant difference (P   0.05) between 
untreated and cardiotoxin-injected muscles (black bars) of  1syn
 /  
mice. **Significant difference (P   0.05) from cardiotoxin-injected 
muscles (hatched bars) of wild-type mice.1100 The Journal of Cell Biology | Volume 158, Number 6, 2002
in  1syn
 /  toxin–injected muscles. The mean in wild-type
toxin-injected muscles was much smaller than contralaterals
at 4 wk after injection.
The shift of MHC isoform expression in skeletal muscle 
from  1syn
 /  mice during regeneration 
To identify the fiber type in the regenerating muscle of the
mutant mice quantitatively, we examined the MHC isoform
composition in skeletal muscle from  1syn
 /  mice during
regeneration using 8% polyacrylamide gel containing glyc-
erol. Although there was no gross difference between the
proportions of MHC isoforms in the untreated wild-type
and mutant muscles, the level of MHC IIa was significantly
lower at 7 d after the cardiotoxin injection compared with
that of wild-type muscle (Fig. 4 a). In contrast, MHC IIb
and IIx levels were slightly higher in the mutant mice at this
stage. In the mutant mice, although the MHC isoform com-
position shifted from slow to fast type at 7 d, they returned
to the same levels as control mice 4–8 wk after the injection.
At 7 d after the treatment, narrow bands corresponding to
MHC neonatal were also detected between MHC IIx and
IIb in both the wild-type and mutant lanes, but they were
not significantly different between genotypes. The results
were shown in Table I.
The level of insulin-like growth factor-1 mRNA was 
elevated in regenerating muscles
Because there were many hypertrophied fibers in regenerat-
ing TA muscle of  1syn
 /  mice, we investigated whether
insulin-like growth factor (IGF)-1 was involved in muscle
hypertrophy of  1syn
 /  mice. We examined the expression
of IGF-1 mRNA in regenerating TA muscles at 2 and 4 wk
after the toxin injection (Fig. 5). In untreated muscles, there
was no significant difference in the expression of IGF-1
mRNA between  1syn
 /  and wild-type mice. In contrast,
the levels of IGF-1 transcripts in regenerating muscles of
 1syn
 /  at 2 and 4 wk after cardiotoxin injection were sig-
nificantly higher than those of wild-type mice, suggesting
IGF-1 may be one of the major factors which induce hyper-
trophy in regenerating mutant muscle. In wild-type mice,
the IGF-1 mRNA level was elevated at 2 wk but had re-
turned to the control level at 4 wk after injection.
Figure 3. Frequency distribution of the fiber CSA in TA muscle at 4 wk after cardiotoxin injection. A total of 200 fiber profiles were traced 
in each section for three muscles from mice of approximately the same body weight. Each fiber was classified by the expression of MHC IIa 
(white bars), MHC IIx (hatched bars), or MHC IIb (black bars) isoform. Arrow shows the mean of fiber CSA.
Table I.  Relative MHC protein content of regenerating TA muscle in wild-type and  1syn
 /  mice
Wild-type  1syn
 / 
Group Noninjected 1 wk 4 wk 8 wk postinjection Noninjected 1 wk 4 wk 8 wk postinjection
Type I  0.54   0.42 0.81   0.72  0.12    0.12 0.20   0.20 0.00   0.00 0.20   0.20 0.03   0.02 0.00   0.00
Type IIa 0.00   0.00 6.33   0.50 0.33   0.33 0.02   0.02 0.00   0.00 1.37   1.37
a  0.00    0.00 0.00   0.00
Type IIx  31.78   0.36 29.03   1.13 38.72   1.47 31.58   0.15 32.38   0.43 33.54   1.61 38.91   2.58 31.62   0.67
Type IIb 67.67   0.63 63.83   1.57  60.48   1.19 68.20   0.05 67.62   1.44 64.89   2.30 60.83   2.58 68.38   0.53
Values are mean   SEM. n   3–7 for each group.
aP   0.05 compared with ctx-injected TA muscles of wild-type mice by Student’s t test. Abnormal regeneration of  1-syntrophin–deficient muscle | Hosaka et al. 1101
 1-Syntrophin–deficient mice were impaired in 
exercise endurance in the early phase of regeneration
To test the exercise endurance of  1syn
 /  mice during the
aberrant muscle regeneration process, we employed a wire
net holding test (Fig. 6). Although all untreated mice of
both wild-type and  1syn
 /  mice completed a maximum
holding time of 5 min in the test (Fig. 6 a), the time of
 1syn
 /  male mice (38.1   15.2 s) was significantly
shorter (P    0.05) than that of wild-type male mice
(151.0   38.2 s) at 7 d after cardiotoxin injection (Fig. 6 b).
 1syn
 /  female mice showed almost the same fatigability as
male mice. We could not detect any difference between ge-
notypes at a later time point (4–8 wk after treatment) (un-
published data).
Tetanic force and isomeric twitch force were much 
reduced in the regenerating muscles of  1syn
 /  mice
To test the hypothesis that hypertrophy of regenerating
 1syn
 /  muscle might be related to reduced force pro-
duction, we next examined the maximal tetanic force and
the peak twitch force of  1syn
 /  and wild-type regenerat-
ing muscles at 4 wk after cardiotoxin injection. The results
are summarized in Table II. Although the specific tetanic
force and the specific twitch force of  1syn
 /  untreated
muscle were not significantly different from those of wild-
type control muscle, those of  1syn
 /  regenerating mus-
cle were significantly reduced compared with those of un-
treated muscles.
Figure 5. Changes in IGF-1 mRNA level in TA muscles after 
cardiotoxin injection. The top panel shows the IGF-1 mRNA 
Northern blot analysis for three muscles/group. G3PDH mRNA 
was used as a control. RNA was obtained from noninjected (a) 
and cardiotoxin-injected muscles of wild-type mice at 2 wk (b) 
and 4 wk (c) after injection. Untreated (d) and cardiotoxin-
injected muscles of  1syn
 /  mice at 2 wk (e) and 4 wk (f) after 
injection were also analyzed. The bottom panel shows the 
increase of IGF-1 mRNA over untreated wild-type muscles. IGF-1 
mRNA level was normalized to G3PDH mRNA level. Values are 
mean   SEM for four samples/group. *Significant difference 
(P   0.05) between wild-type (white bars) and  1syn
 /  mice 
(black bars).
Table II.  Contractile force of TA muscles at 4 wk after ctx injection
Wild-type   1syn
 / 
Parameter Noninjected Injected Noninjected Injected
L0, mm 11.82   0.53 11.19   0.37 11.15   0.44 11.01   0.47
TA weight, mg 15.40   1.10 17.10   1.56 14.71   1.20 17.95   1.28
a
TA CSA, mm
2 1.23   0.05 1.38   0.08 1.27   0.12 1.56   0.11
a,b
Twitch force, mN 43.75   10.01 69.55   14.13
a 41.89   5.10 35.32   4.51
c
Tetanic force, mN 145.29   32.67 217.59   32.18
a 140.90   18.05 127.72   14.91
c
Specific twitch force, mN/mm
2 35.57   8.14 50.40   10.24 33.00   4.02 22.64   2.89
a,c
Specific tetanic force, mN/mm
2 118.01   28.25 161.17   23.84
a 110.95   16.09 79.95   10.89
a,c
Values are mean   SEM. n = 5–8 for each group.
aP   0.05 compared with contralateral noninjected TA muscles.
bP   0.01.
cP   0.001 compared with ctx-injected TA muscles of wild-type mice by Mann-Whitney’s U test. 
Figure 4. MHC contents in wild-type and  1syn
 /  regenerating 
TA muscles. Electrophoretic separation of wild-type and  1syn
 /  
TA muscle MHCs at 7 d (a) and 4 wk (b) after cardiotoxin 
injection, and nontreated muscle (c). Representative silver-stained 
SDS–polyacrylamide gel shows a significantly lower level of MHC 
IIa and slightly higher levels of IIb and IIx in  1syn
 /  muscle at 7 d 
after injection.1102 The Journal of Cell Biology | Volume 158, Number 6, 2002
 1syn
 /  skeletal muscle showed aberrant NMJs in the 
regeneration process
Since  1-syntrophin is strongly expressed at NMJs (Peters et
al., 1997), we examined the morphology and utrophin ex-
pression at NMJs in  1syn
 /  skeletal muscle in regenera-
tion. Alexa 594–labeled  -bungarotoxin ( -BgTx) was used
to identify NMJs. Regenerating TA muscle of  1syn
 /  mice
had remarkably shallow nerve gutters at NMJs, although the
untreated mutant mice showed moderate abnormality (Fig.
7). Interestingly, the localization of utrophin in the mutant
mice (Fig. 7 p) was not completely coincident with that of
AChR (Fig. 7 q), especially at 8 wk after injection.
Expression of  1-syntrophin,  1-syntrophin, neuronal 
NOS, AQP4, voltage-gated sodium channel, caveolin-3, 
and  -dystrobrevin in muscle regeneration of wild-type 
and  1syn
 /  mice
 1-Syntrophin has been reported to interact with several
signaling molecules or channels. To clarify whether these
molecules are involved in the mechanism of force deficit
and hypertrophy seen in  1syn
 /  regenerating muscle, we
examined the expression of these molecules during regener-
ation. In wild-type mice, sarcolemmal expression of  1-
syntrophin was detected in muscles of untreated mice and
at 4 wk after cardiotoxin injection (Fig. 8, a and b). In
 1syn
 /  mice, we detected no signal at the sarcolemma;
however, a trace of putative truncated  1-syntrophin was
detected at NMJs (Fig. 8, c and d). Immunohistochemistry
showed that  1-syntrophin was overexpressed in fast-type
myofibers in the mutant mice (Fig. 8 g). Western blotting
analysis confirmed modest up-regulation of  1-syntrophin
in the mutant mice (unpublished data). In the regeneration
process, the level and expression pattern of  1-syntrophin
in mutant muscle was not different from those of wild-type
muscle (Fig. 8, f–h).  2-Syntrophin was enriched at NMJs
in both wild-type and the mutant muscles, and the expres-
Figure 6. Impaired ability of  1syn
 /  mice in wire net holding 
test at 7 d after cardiotoxin injection. Maintenance time in the test 
of untreated mice (a) or cardiotoxin-injected mice (b) at 7 d after the 
treatment.  1syn
 /  mice are impaired in their ability to perform the 
exercise at the early stage of the regeneration process. Values are 
mean   SEM. *Significant difference (P   0.05) between 
cardiotoxin-injected mice of  1syn
 /  and wild-type.
Figure 7. Aberrant formation of NMJs in regenerating  1syn
 /  
muscle. Structure of NMJs in 6- m cryosections of  1syn
 /  (d–f, j–l, 
and p–r) and wild-type (a–c, g–i, and m–o) TA muscle of untreated 
mice (a–f), at 7 d (g–l), or three dimensional reconstructed images of 
NMJ in a single fiber at 8 wk (m–r) after cardiotoxin injection. 
Specimens are double labeled with antiutrophin antibody (a, d, g, j, m, 
and p) and Alexa 594– -BgTx (b, e, h, k, n, and q). The two images 
are merged to show the relative positions of each molecule (c, f, i, l, 
o, and r). The mutant mice have remarkably shallow gutters at the 
NMJs from the early stage of regeneration at 7 d after injection. 
Moreover, in the mutant mice, the localization of utrophin is not 
coincident with that of AChR at 8 wk after the treatment. Bar, 20  m. Abnormal regeneration of  1-syntrophin–deficient muscle | Hosaka et al. 1103
sion of  2-syntrophin in regenerating mutant muscle was
not different from that of wild-type muscle (unpublished
data). Reduced expression of nNOS at the sarcolemma was
recognized in a mosaic pattern from 2 wk after injection
(Fig. 8 j). However, the expression of nNOS was not de-
tected at the sarcolemma in either treated or untreated mus-
cles of  1syn
 /  mice (Fig. 8, k and l). The water channel
AQP4 has been reported to be absent at the sarcolemma of
 1syn
 /  mice (Yokota et al., 2000) and in mdx muscle
(Frigeri et al., 1998; Liu et al., 1999). AQP4 expression at
the sarcolemma started as early as 2 wk after toxin injection
in wild-type regenerating muscle (Fig. 8 n). In contrast to
the proper localization of AQP4 at the sarcolemma of neo-
natal  1syn
 /  muscle (Yokota et al., 2000), AQP4 expres-
sion was completely absent from the sarcolemma in mutant
regenerating muscle (Fig. 8 p). An antibody against voltage-
gated sodium channel (VGSC) stained NMJs intensely in
 1syn
 /  and wild-type regenerating muscle as early as 1
wk after cardiotoxin injection (Fig. 8, q–t). Caveolin-3 has
been reported to interact with nNOS and modify its enzy-
matic activity at the sarcolemma (Venema et al., 1997). In
regenerating muscles of wild-type and mutant mice, it was
normally expressed at the sarcolemma (Fig. 8, v and x). Ad-
ams et al. (2000) reported that sarcolemmal expression of
 -dystrobrevin-2 was slightly reduced in  1syn
 /  muscles.
However, our results showed that the expression of  -dys-
trobrevin in  1syn
 /  was indistinguishable from that of
wild-type in both regenerating and untreated muscles (Fig.
8, y–ab). By Western blotting analysis, we could not detect
any difference between the levels of  -dystrobrevin-1 and
-2 in wild-type and in the mutant mice in both conditions
(unpublished data).
Discussion 
 1syn
 /  mice show hypertrophy in muscle regeneration
Regenerating  1syn
 /  muscles clearly exhibited extensive
hypertrophy from 2 to 8 wk after intramuscular injection of
cardiotoxin. Similar hypertrophies of muscle fibers are also
seen in  -sarcoglycan–deficient mice (Duclos et al., 1998),
dystrophin-utrophin double deficient mice (Deconinck et
al., 1997), and mdx mice (Coulton et al., 1988), together
with reduced specific contractile force. Animal models such
as functional overload via synergist ablation can also produce
a significant increase in the mass of the overloaded muscles
(Timson, 1990). In humans, abnormal muscle hypertro-
phy is seen in slow twitch skeletal (soleus) muscle of pa-
tients with hypertrophic cardiomyopathy (Fananapazir et al.,
1993: Lankford et al., 1995), in skeletal muscle in patients
with sarcoglycan deficiency (Sewry et al., 1996), and in early
stages of DMD (Hardiman, 1994). In the case of hyper-
trophic cardiomyopathy, which is linked to the  -myosin
heavy chain gene, the mutated MHCs in slow twitch skeletal
muscle have a significant effect on the muscle contractile
profile. These hypertrophic processes can be an adaptive re-
sponse to the decreased contractile force. Interestingly,
Lynch et al. (2001) showed that 6–28-mo-old mdx mice dis-
played hypertrophy with normal absolute tetanic force. On
the other hand, the absolute tetanic force of 3-mo-old mdx
muscle is significantly less than that of normal muscle de-
spite the significant hypertrophy (Barton et al., 2002). These
observations indicate that the absolute tetanic force of mdx
increases after 3 mo old, although that of wild-type mice is
almost unchanged. In the treated  1syn
 /  mice, the abso-
lute tetanic force was significantly less than in the untreated
 1syn
 /  mice despite the significant hypertrophy. In this
point, regenerating muscle of  1syn
 /  mice may display a
similar situation with 3-mo-old mdx muscles. IGF-1 is up-
regulated in the case of regenerating  1syn
 /  muscles (Fig.
5) and in mdx mice (De Luca et al., 1999). Interestingly,
mdx mice showed restoration of tetanic force when hyper-
trophy was induced by IGF-1 as a transgene, though the
specific force of the mice (per area) was not different from
that of mdx mice (Barton et al., 2002). These reports suggest
that IGF-1 can restore the total tetanic force but cannot re-
store the specific force by inducing hypertrophy.
MHC composition in the regenerating  1syn
 /  muscle
Interestingly, the cardiotoxin-injected mutant mice showed
a marked deficit in exercise capacity at 7 d compared with
the treated wild-type mice. Reduced exercise capacity has
also been shown in mdx mice by the wire net test. The de-
Figure 8. Expression of  1-syntrophin and its relevant proteins in 
wild-type and  1syn
 /  regenerating muscles. Expression of 
 1-syntrophin (a–d),  1-syntrophin (e–h), nNOS (i–l), AQP4 (m–p), 
VGSCs (q–t), caveolin-3 (u–x), and  -dystrobrevin (y–ab) in TA 
muscles. Untreated muscle of wild-type (a, e, i, m, q, u, and y) and 
 1syn
 /  mice (c, g, k, o, s, w, and aa). Cardiotoxin-injected muscle 
of wild-type (b, f, j, n, r, v, and z) and  1syn
 /  mice (d, h, l, p, t, x, 
and ab) at 4 wk after injection. Bar, 50  m.1104 The Journal of Cell Biology | Volume 158, Number 6, 2002
creased capacity in regenerating  1-syntrophin knockout
mice can be, at least partly, explained by the alteration of
MHC composition. In the mutant regenerating muscles, the
temporal increase of MHC I and IIa has been considerably
inhibited and results in a relative increase of MHC IIb ex-
pression. A relative decrease of slow components at this pe-
riod may affect the stamina of mutant mice in the test.
In mdx muscle, the reduced contractile force has been ex-
plained by the decreases in the proportion of type IIx and in-
creases in type I MHC (Coirault et al., 1999). However,  1-
syntrophin knockout mice did not exhibit altered MHC
composition at 4–8 wk after the cardiotoxin injection. Actu-
ally, we observed predominant hypertrophy of type IIb fi-
bers at the period by immunohistochemistry, whereas glyc-
erol SDS-PAGE did not detect a significant increase of
MHC IIb. This suggests that the hypertrophied mutant type
IIb fibers contain considerable amounts of MHC IIx, since
MHC IIx transcripts are abundant in histochemical type IIb
fibers (Smerdu et al., 1994). Therefore, the composition of
MHC cannot explain the reduced contractile force in the re-
generation period of mutant mice.
Possible mechanisms of the reduction of contractile 
force in the regenerating  1syn
 /  muscle
In mdx muscle, deficiency in exercise capacity, reduced con-
tractile force production, and muscle hypertrophy (Coulton
et al., 1988; Carter et al., 1995) can be related to the occur-
rence of many cycles of muscle degeneration and regenera-
tion, membrane fragility, or reduced amount of myofibrils. In
contrast, regenerating  1syn
 /  TA muscles show no evi-
dence of muscle degeneration, fibrosis, or loss of myofibers
(Kameya et al., 1999). In addition, our examination showed
no evidence of delay in maturation of myofibers. Therefore,
we speculate that abnormal regeneration of syntrophin-null
muscle is mainly caused by the lack of functional molecules
that interact with  1-syntrophin. We have shown previously
that two molecules are lacking from the sarcolemma of
 1syn
 /  muscle in vivo. First, nNOS was completely absent
from the sarcolemma in  1syn
 /  muscle (Kameya et al.,
1999). Could nNOS be the molecule responsible for the re-
duction of contractile force in  1syn
 /  muscle? NO is
widely accepted as a versatile regulator of muscle functions
through the cGMP pathway (Kobzik et al., 1994). It has been
suggested that NO generated by nNOS at the sarcolemma
regulates contraction-stimulated glucose uptake (Roberts et
al., 1997) or increases local blood flow in contracting skeletal
muscle in part by antagonizing sympathetic vasoconstriction
(Thomas et al., 1998). Recently, NO has been reported to
protect dystrophin-deficient mdx muscle from degeneration
when expressed at a high level (Wehling et al., 2001). More-
over, NO can modulate the force–frequency relationship in
skeletal muscle (Stamler and Meissner, 2001). However, at
least in in vitro studies, NO depletion results in an increase of
contractile force (Stamler and Meissner, 2001), whereas
 1syn
 /  muscle showed the opposite response in the regen-
eration process. Thus, the loss of nNOS from the sarcolemma
may not be directly responsible for the decline in contractile
force of the regenerating muscle in the mutant mice. We have
shown already that  1-syntrophin plays a major role in re-
cruiting a water channel, AQP4, to the sarcolemma in fast
twitch muscle fibers (Yokota et al., 2000). VGSC (Schultz et
al., 1998; Gee et al., 1998), stress-activated protein kinase 3
(Hasegawa et al., 1999), and phosphatidylinositol 4,5-bis-
phosphate (Chockalingam et al., 1999) can also bind to  1-syn-
trophin. Therefore, it is possible that one or more of these
molecules are responsible for the abnormal regeneration, al-
though there is no direct evidence for the involvement of
these proteins in contractile force production.
The alternate explanation for this phenomenon is that ab-
errant NMJs formation in the  1syn
 /  mice may affect the
force generation of regenerating muscle. Interestingly, a spe-
cific force deficit caused not only by atrophy but also by
other unknown mechanism(s) exists in skeletal muscle after
denervation (Kalliainen et al., 2002).
Finally, proteins involved in excitation-contraction cou-
pling might be responsible for this reduction of contractile
property in the mutant regenerating muscle. However, the
protein responsible for the deficit in contractile force genera-
tion in the mutant mice remains to be determined.
Aberrant formation of NMJs in regenerating 
TA muscle of  1syn
 / 
Our results and a previous report (Adams et al., 2000) dem-
onstrated that  1-syntrophin plays an important role in for-
mation of highly organized NMJs both in the developmental
process and in muscle regeneration. Since  1-syntrophin is a
PDZ protein without any known catalytic domain, the mole-
cules play their roles in NMJ formation by sorting several
structural or signaling molecules at the synaptic membrane.
Adams et al. (2000) reported that utrophin was severely
down-regulated at the NMJs in their  1syn
 /  mice, suggest-
ing that  1-syntrophin is an important regulator of utrophin
expression at NMJs. It is reasonable to conclude that aberrant
NMJs in  1syn
 /  muscle are due to the deficiency of utro-
phin, since utrophin-null muscle showed similar aberrant
NMJs to those of  1syn
 /  mice (Deconinck et al., 1997;
Grady et al., 1997). However, our results showed that the
level of utrophin expression is not reduced at the NMJs in
the absence of  1-syntrophin in either nonregeneration or re-
generation (Fig. 7). This discrepancy in utrophin expression
might be derived from a difference in the targeting strategy of
the  1-syntrophin gene. We inserted an NEO gene in the sec-
ond exon encoding the PDZ domain (Kameya et al., 1999)
and later detected a trace of truncated, PDZ-less  1-syntro-
phin at NMJs (Fig. 8). Ahn and Kunkel (1995) reported that
the COOH-terminal fragment conserved among the three
syntrophin homologues is sufficient to interact with utro-
phin. Therefore, it is possible that PDZ-less  1-syntrophin at
NMJs recruits utrophin at the sarcolemma. Thus, the most
prominent feature of NMJs in  1syn
 /  muscle, shallow gut-
ters, is not explained by the lack of utrophin expression. At
the same time, we should point out that AChR is not colocal-
ized with utrophin/dystrophin-associated proteins at the
NMJs in  1syn
 /  muscle on confocal microscopic analysis
(Fig. 7). Therefore,  1-syntrophin might play a role in for-
mation of highly organized NMJs by targeting functional
molecules other than utrophin at the synaptic membrane.
 1-Syntrophin might interact with other PDZ proteins such
as membrane-associated guanylate kinase with inverted do-
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might interact with another class of proteins, one which has a
consensus sequence in its COOH-terminal (S/T/V-X-V-
COOH) to interact with the PDZ domain, such as ErbB4
(Zhu et al., 1995) or muscle-specific receptor tyrosine kinase
(Torres et al., 1998), at NMJs. Aberrant NMJs and deficits
in exercise capacity in  1syn
 /  mice were observed from an
early stage of regeneration. Moreover, the temporal increase
of slow muscle components early in the regenerating process
might be regulated by the influence of slow nerves. There-
fore, aberrant NMJs may be partly responsible for the deficit
in exercise capacity of  1syn
 /  mice.
The role of  1-syntrophin in skeletal muscle 
development and regeneration
Is aberrant NMJ formation related to muscle hypertrophy
and/or reduced contractile force in the regeneration process?
Mutant skeletal muscle showed neither hypertrophy nor re-
duced contractile force in the developmental stage without
cardiotoxin treatment, although they do have aberrant
NMJs. However, in regeneration hypertrophy becomes ap-
parent 2 wk after toxin treatment, and the shallower synap-
tic gutter and enlargement of NMJs became more apparent
at 4–8 wk after cardiotoxin treatment in  1syn
 /  muscles
(unpublished data). This disparity between developmental
stage and regeneration process in  1syn
 /  mice may be
caused by the difference of expression patterns of  1-syntro-
phin and its associated factors between developmental and
regeneration processes. AQP4 is abundantly expressed in the
neonatal stage without accompanying expression of  1-syn-
trophin (Yokota et al., 2000), but it is not expressed until
later in the regeneration process as shown in this study.
AQP4 may not be related directly to hypertrophy and re-
duced contractile force in the regeneration process of
 1syn
 /  mice, but other molecules can show the same pat-
tern of expression and explain the peculiar phenomenon.
Accordingly,  1-syntrophin and its related molecules may
have a particular role in regeneration, rather than in devel-
opment, of skeletal muscle.
Muscular dystrophy and muscle hypertrophy
The primary absence of dystrophin is accompanied by a
secondary deficiency of several dystrophin-associated mole-
cules, including  - and  -dystroglycans, sarcoglycans, sarco-
span, syntrophins, and dystrobrevins, from the sarcolemma
(Ozawa et al., 1995). Therefore, molecular dissection of asso-
ciated molecules by gene targeting is a powerful tool to clarify
the molecular pathogenesis of muscular dystrophy. In partic-
ular, the expression of dystrophin-associated proteins other
than nNOS is well preserved in  1syn
 /  mice; therefore,
the mutant mice are a good model to examine the functions
of  1-syntrophin and its own downstream elements both in
physiological and pathological conditions. In the present
study, we clearly demonstrated that  1-syntrophin plays an
important role in muscle regeneration: in the absence of  1-
syntrophin, regenerating muscle showed a marked decrease
in the exercise capacity and contractile force and an increase
in muscle hypertrophy and aberrant NMJ formation. DMD
patients and all dystrophin-deficient models (dogs, cats, and
mice) pass through an early phase of muscle hypertrophy to
some extent (Partridge, 1991). The deficit caused by the lack
of  1-syntrophin may largely account for the phenomenon
found in the early regeneration stage of DMD.
Materials and methods
Animals
8-week-old  1syn
 /  (Kameya et al., 1999) and wild-type littermates were
used in this study. The animals were allowed ad libitum access to food and
drinking water. Mice carrying mutations were identified by Southern blot
analysis as described (Kameya et al., 1999). 
Cardiotoxin injection and tissue preparation
0.1 ml of 10  M cardiotoxin (Wako Pure Chemical Industries) in 0.9% sa-
line was injected directly into the right TA muscle with a 27-gauge needle
under ether anesthesia. Mice were killed by cervical dislocation, and the
cardiotoxin-injected TA muscles (right) and noninjected contralateral TA
muscles (left) were removed for analysis at 1, 3, and 5 d, and 1, 2, 4, 8, 12,
and 24 wk after injection. Body weight and wet muscle weight (TA) were
measured. Several of the muscles were frozen in isopentane cooled by liq-
uid nitrogen for histological, immunohistochemical analysis, and the other
muscles were frozen directly in liquid nitrogen for RNA isolation, and
stored at  80 C.
Hematoxylin and eosin staining
10- m cryosections were cut in the middle part of the muscle belly to obtain
the largest CSA, placed on poly-L-lysine–coated slides, air dried, and stained
with hematoxylin and eosin. The sections were viewed and photographed
using an HC-2500 digital camera system™ (Fuji Photo Film Co., Ltd.).
Single muscle fiber isolation
We isolated single muscle fibers according to the method described previ-
ously (Rosenblatt et al., 1995) with a simple modification. In brief, the TA
muscle was rinsed in PBS, put into a Petri dish containing 0.5% type I col-
lagenase (Worthington Biochemical Corp.) in DME (Invitrogen), and incu-
bated at 37 C for 1.5–3 h.
Immunohistochemical analysis
Antibodies. Monoclonal antibodies BF-B6, BA-D5, or BF-F3 obtained from
DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen Abt.
Menschliche und Tierische Zellkulturen) detect neonatal type MHC,
MHC I, or MHC IIb, respectively. Monoclonal antibody SC-71 (DSM)
strongly labels MHC IIa and labels MHC IIx to a lesser extent. We con-
cluded that the fibers negative for BA-D5, BF-F3, and SC-71 antibodies
were type IIx. The following polyclonal antibodies were used for immun-
ofluorescence: anti– 1-syntrophin (Asahi Techno Glass Co., Ltd.), anti-
myogenin (Santa Cruz Biotechnology, Inc.), anti–Myf-5 (Santa Cruz Bio-
technology, Inc.), anti–Myf-6 (Santa Cruz Biotechnology, Inc.), anti-
MyoD (Santa Cruz Biotechnology, Inc.), antiutrophin (Imamura and
Ozawa, 1998), anti–caveolin-3 (Asahi Techno Glass Co., Ltd.), anti-NOS1
(Santa Cruz Biotechnology, Inc.), anti–sodium channel (III-IV Linker Re-
gion) (Upstate Biotechnology), and anti– -dystrobrevin-1 and -2 (Yoshida
et al., 2000). Human  1-syntrophin (195–378 a.a.) was fused to GST in
the pGEX vector (Amersham Biosciences) and maltose-binding protein in
the pMAL-c2 vector (New England Biolabs, Inc.). The GST fusion  1-syn-
trophin protein was used as an antigen. Obtained rabbit antiserum was
purified with the affinity column coupled with the maltose-binding pro-
tein– 1-syntrophin fusion protein. The last 43 amino acids of mouse
AQP4 were fused to GST in the pGET 1 T vector (Amersham Bio-
sciences), and the recombinant proteins were purified and used to obtain
rabbit polyclonal antibodies.
Immunofluorescence. Acetone-fixed cryosections (6  m) were blocked
with 5% goat serum and 2% BSA in PBS and then incubated with primary
antibody at 4 C overnight. 4% paraformaldehyde-fixed single muscle fi-
bers were blocked with 20% goat serum in PBS and then incubated with a
primary antibody in 0.35% carrageenan in PBS at 4 C overnight. FITC-
conjugated anti–rabbit goat antibody (Biosource International) or Alexa
488–labeled goat anti–rabbit IgG (H L) (Molecular Probes) was used as
the secondary antibody. To identify NMJs, AChRs were detected with Al-
exa 594–labeled  -BgTx (Molecular Probes). The sections were viewed
and photographed by a laser scanning microscope, FLUOVIEW™ (Olym-
pus). Z serial images were collected from whole-mount single fiber sam-
ples with a 63  oil objective using TCSSP™ (Leica). A single projected im-
age was created by overlaying each set of z series images.1106 The Journal of Cell Biology | Volume 158, Number 6, 2002
Northern blot analysis of IGF-1
A First-Strand cDNA Synthesis kit™ (Amersham Biosciences) was used to
synthesize first strand cDNA from total RNA isolated from TA muscles of
wild-type mice. IGF-1 cDNA was amplified by PCR using two oligonu-
cleotide primers (5 -GTCTTCACACCTCTTCTACC-3  and 5 -CCTTCT-
GAGTCTTGGGCATGTCAG-3 ). A 320-base pair PCR product covering
exon 3 and part of exon 4 of the IGF-1 gene was cloned into a pCR
R 2.1
vector (Invitrogen) and confirmed by sequencing using a DNA analysis sys-
tem LIC-4200L-2™ (LI-COR, Inc.). Glyceraldehyde-3-phosphate dehydro-
genase (G3PDH) cDNA was amplified using RT-PCR Control Amplimer
Set™ (CLONTECH Laboratories, Inc.) and cloned as described above. The
cDNA fragment was digested with EcoRI (TaKaRa Shuzo Co., Ltd.) and la-
beled with 
32P using a Random Primer DNA Labeling kit version 2™
(TaKaRa Shuzo Co., Ltd.). Total RNA was prepared from TA muscles by us-
ing RNAzol™ B (TEL-TEST, Inc.). 30  g of total RNA was electrophoresed
on a 1.0% denaturing agarose-formaldehyde gel, transferred to Hybond N
 
nylon membrane™ (Amersham Biosciences) and heated at 80 C for 2 h.
The hybridization was performed using 
32P-labeled DNA probes. Prehy-
bridization (30 min) and hybridization (overnight) were performed at 42 C
in ULTRAhyb™ hybridization buffer (Ambion). Washing was performed for
2   5 min at 42 C with 2   SSC and 0.1% SDS, 2   15 min at 42 C with
0.1   SSC and 0.1% SDS. The hybridized probe was detected and quanti-
fied using the Bio-Imaging analyzer BAS-2500™ (Fuji Photo Film Co., Ltd.).
Measurement of fiber CSA
The CSA of each fiber classified by the expression of MHC was measured
using a Mac SCOPE™ (Mitani Co.). We measured fiber CSA on the sec-
tions from three muscles in each group (noninjected and cardiotoxin-
injected wild-type and  1syn
 /  mice). A total of 200 fiber profiles were
measured in the predetermined area of TA muscles. All fiber profiles traced
in each group of muscles were pooled and plotted for their size distribu-
tion according to percent frequency. 
Wire net holding test
The untreated male mice of 8-wk-old wild-type (n   3) and  1syn
 /  (n  
3) or the mice at 7 d–8 wk after cardiotoxin injection into TA muscles of
hind legs of 8-wk-old wild-type (n   13) and  1syn
 /  (n   8) were exam-
ined. The mice were placed on a fine wire net. Then, the net was slowly
turned over. The time until the mouse fell off was measured up to a maxi-
mum time of 300 s.
MHC isoform separation
The muscles frozen in isopentane cooled by liquid nitrogen were homoge-
nized and extracted on ice for 60 min in 4 vol of buffer (pH 6.5) as de-
scribed previously (Butler-Browne and Whalen, 1984). MHC separation
on polyacrylamide gels containing 30% glycerol was performed according
to the methods described previously (Agbulut et al., 1996) with simple
modification. In brief, mini gels were made in the mini protein III Dual slab
cell system (Bio-Rad Laboratories Inc.). 0.5  g of total protein was run on
each well. The upper buffer contained 10 mM of 2-mercaptoethanol. Dur-
ing electrophoresis, the temperature of the buffer was maintained at 5 C.
After migration, the gels were silver stained using 2D-Silver Stain II “Daii-
chi” (Daiichi Pure Chemicals Co., Ltd.). The image was scanned and then
analyzed using Lumi-Imager F1 software (Hoffmann-La Roche, Inc.).
Muscle physiology
Tetanic force and isometric twitch force of TA muscles were measured as
described previously (Xiao et al., 2000). The entire TA was removed with
its tibial origin intact, and the distal portion of the TA tendon and its origin
were secured with a 5–0 silk suture. The TA was mounted in a vertical tis-
sue chamber and was connected to a force transducer UL-50GR (Micro-
tech) and length servosystem (Shimazu). Electrical stimulation using a
SEN3301 (Nihon Kohden) was applied through a pair of platinum wires
placed on both sides of the muscle in physiological soft solution (150 mM
NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, 5 mM
Hepes, pH 7.4, 0.02 mM D-tubocurarine). The TA was positioned midway
between the two electrodes. Muscle fiber length was adjusted incremen-
tally by using a micropositioner until peak isometric twitch force (Pt) re-
sponses were obtained (i.e., optimal fiber length [L0]). The dependence of
force generation on the rate of stimulation and maximum tetanic force (P0)
was assessed by use of a range of stimulation frequencies (20, 50, 75, and
100 pulses per second) delivered in 500-ms duration trains with 2 min in-
tervening between each train. After these measurements, the stimulated
muscle was dried and weighed after tendon and bone attachments were
removed. All forces were normalized for a dried CSA, the latter estimated
on the basis of the following formula: dried muscle weight (in milligrams)/
[L0 (in millimeters)   1.056 (in milligrams per cubic millimeter)]. The esti-
mated CSA was used to determine specific twitch forces (Pt/CSA) and spe-
cific tetanic forces (P0/CSA) of the muscles.
Statistical analysis
The relative weight of muscle, the number of myofibers and the expression
of IGF-1 mRNA, the holding time on the wire net holding test, and the lev-
els of MHC protein isoforms between wild-type and  1syn
 / , noninjected
and cardiotoxin-injected muscle were compared using Student’s t test.
CSA distributions and mean fiber CSA were compared using F test and Stu-
dent’s or Welch’s t test. P   0.05 was considered statistically significant.
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